Peptide blend · Research Monograph · Two-compound metabolic blend: GLP-2 + Cagri (5 mg each)

GLP-2 / Cagri

Incretin + amylin blend · 10 mg lyophilized

This is a blend. GLP-2 and Cagri are combined in a single 10 mg vial, 5 mg of each. GLP-2 is a dual GIP/GLP-1 receptor research compound; Cagri is a long-acting amylin-analog research compound. The pairing places an incretin arm and an amylin arm in one vial. The combination itself has not been characterised as a single entity.

Size
5mg / 5mg
Form
Lyophilized powder blend
View product & pricing → Lot records & COAs

For laboratory research use only - not for human or animal use

GLP-2 / Cagri vial from the Eon Peptides research catalog
GLP-2 / Cagri · 5mg / 5mg · catalog photograph
Available in the Eon catalog - GLP-2 / Cagri from $95.00

Molecular data

Physical formLyophilized powder blend
Available sizes5mg / 5mg

How it works

  1. GLP-2

    Dual Incretin Receptor Activity

    Co-agonism at the GIP and GLP-1 receptors is characterised, with glucose-dependent insulin release as the primary measured readout.

    • GIP receptor engagement
    • GLP-1 receptor engagement
    • Gastric-emptying endpoints
  2. Cagri

    Amylin Receptor Signalling

    Amylin analogs are characterised at the calcitonin and amylin receptor complexes, with satiety signalling and gastric-emptying rate as measured endpoints.

    • Amylin receptor complexes
    • Satiety signalling
    • Gastric-emptying rate
  3. Combined

    Parallel Pathway Coverage

    The vial places an incretin arm and an amylin arm under matched handling. No interaction between the two has been characterised.

    • Two distinct pathways
    • Matched storage
    • Interaction not characterised

What the research shows

  1. Metabolic

    Satiety Signalling Models

    Amylin-analog literature measures satiety signalling and food-intake endpoints in preclinical models.

  2. Metabolic

    Glucose Handling

    The incretin arm is studied for glucose-dependent insulin release.

  3. Gastroenterology

    Gastric Emptying

    Both arms carry gastric-emptying endpoints in the published literature.

  4. Methods

    Parallel-Arm Protocols

    One vial supports protocols that need both pathway arms under matched conditions.

Specification

ComponentsGLP-2 + Cagri
Content10 mg per vial (5 mg of each component)
PathwaysIncretin (GIP/GLP-1) · amylin
FormLyophilized powder blend
Purity≥99% by HPLC
AppearanceWhite to off-white powder
SolubilityWater-soluble
Storage-20°C, protected from light
ClassificationResearch use only

Frequently asked questions

Why combine an incretin and an amylin compound?

They act through separate receptor systems. Holding both in one vial supports protocols that need an incretin arm and an amylin arm under matched handling.

Has the combination been characterised as a single formulation?

No. Each compound is characterised separately. No interaction data exists for the pair.

What is Cagri?

Cagri is Eon's designation for the long-acting amylin-analog research compound sold individually as Cagri 10 mg.

What purity is documented?

Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.

How is it stored?

Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.

  • KLOWFour-peptide blend · 80 mg lyophilized
  • BPC-157 / TB-500Two-peptide blend · 20 mg lyophilized
  • CJC / IPA BlendTwo-peptide blend · GHRH-R and GHS-R pathways
  • GlowThree-peptide blend · dermal and matrix models

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.